

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2005/000403

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. ⁷: A61K 38/12, A61P 25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, DWPI: C5aR, ANTAGONIST, MODULATOR, INHIBITOR, NEUROLOGICAL, NEURODEGENERATION, CNS, PARKINSON'S, ALZHEIMER'S, WILSON'S

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2005/007087 A2 (NEUROGEN CORPORATION) 27 January 2005 See the whole document, particularly page 42 lines 6-20, page 43 lines 6-11.	1-2, 12-14, 18-19, 23-27, 29-31
X Y	WO 2003/033528 A1 (UNIVERSITY OF QUEENSLAND) 24 April 2003 See the whole document, particularly the abstract, page 8 lines 17-35, and claim 23.	1-19, 23-31 1-31
X Y	EP 1308438 A1 (MITSUBISHI PHARMA CORPORATION) 7 May 2003 See the whole document, particularly the abstract, page 3 lines 38-45, page 5 lines 4-12, page 13 line 15 – page 14 line 30, test example 1, and claims 11-12.	1-2, 12-14, 18-19, 23-27, 29-31 1-31

☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 21 April 2005	Date of mailing of the international search report 05 MAY 2005
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized officer JASON MACKENZIE Telephone No : (02) 6283 7934

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000403

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000 Aug;49(1-2):171-86. See the whole document, particularly the abstract, part 8 starting on page 180, and the last paragraph in part 10 on page 182.	1-31
Y	Farkas I, Takahashii M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, Tateyama H, Yamamoto T, Okada N, Okada H. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol. 2003 Jun 1;170(11):5764-71. See the whole document, particularly the abstract, Figures 5 and 6, and the discussion.	1-31
A	Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience. 1999;88(4):1073-82. See the whole document, particularly the abstract.	1-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2005/000403

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	2005007087				
WO	03033528	CA	2463675	EP	1444251
EP	1308438	AU	77751/01	CA	241 8652
		US	2003207939	WO	021 4265
CN 1466569					
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.					
END OF ANNEX					

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference VS:CE:FP21350	<div style="display: flex; justify-content: space-between;"> <div>FOR FURTHER ACTION</div> <div>see Form PCT/ISA/220 as well as, where applicable, item 5 below.</div> </div>	
International application No. PCT/AU2005/000403	International filing date (day/month/year) 21 March 2005	(Earliest) Priority Date (day/month/year) 26 March 2004
Applicant PROMICS PTY LIMITED et al		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐

The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ Certain claims were found unsearchable (See Box No. II).

3. ☐ Unity of invention is lacking (See Box No. III).

4. With regard to the title,

☐

the text is approved as submitted by the applicant.

☒

the text has been established by this Authority to read as follows: TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS.

5. With regard to the **abstract**,

☒

the text is approved as submitted by the applicant.

☐

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.

as selected by this Authority, because the applicant failed to suggest a figure.

as selected by this Authority, because this figure better characterizes the invention.

- b. ☐

none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000403

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. ⁷: A61K 38/12, A61P 25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, DWPI: C5aR, ANTAGONIST, MODULATOR, INHIBITOR, NEUROLOGICAL, NEURODEGENERATION, CNS, PARKINSON'S, ALZHEIMER'S, WILSON'S

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2005/007087 A2 (NEUROGEN CORPORATION) 27 January 2005 See the whole document, particularly page 42 lines 6-20, page 43 lines 6-11.	1-2, 12-14, 18-19, 23-27, 29-31
X Y	WO 2003/033528 A1 (UNIVERSITY OF QUEENSLAND) 24 April 2003 See the whole document, particularly the abstract, page 8 lines 17-35, and claim 23.	1-19, 23-31 1-31
X	EP 1308438 A1 (MITSUBISHI PHARMA CORPORATION) 7 May 2003. See the whole document, particularly the abstract, page 3 lines 38-45, page 5 lines 4-12, page 13 line 15 – page 14 line 30, test example 1, and claims 11-12.	1-2, 12-14, 18-19, 23-27, 29-31
Y		1-31

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
21 April 2005Date of mailing of the international search report
05 MAY 2005Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

JASON MACKENZIE
Telephone No : (02) 6283 7934

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000403

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000 Aug;49(1-2):171-86. See the whole document, particularly the abstract, part 8 starting on page 180, and the last paragraph in part 10 on page 182.	1-31
Y	Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, Tateyama H, Yamamoto T, Okada N, Okada H. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol. 2003 Jun 1;170(11):5764-71. See the whole document, particularly the abstract, Figures 5 and 6, and the discussion.	1-31
A	Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience. 1999;88(4):1073-82. See the whole document, particularly the abstract.	1-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2005/000403

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	2005007087				
WO	03033528	CA	2463675	EP	1444251
EP	1308438	AU	77751/01	CA	2418652
		US	2003207939	WO	0214265
CN 1466569					
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.					
END OF ANNEX					